BioCardia CEO Peter Altman will present CardiAMP and platform updates at the H.C. Wainwright conference beginning September 14. Investors will receive updates on potential regulatory approval in Japan and the United States, the CardiAMP HF II trial, Helix and Heart3D platforms, plus Business development activity.

Key Highlights

  • BioCardia is preparing a Japan regulatory submission for CardiAMP Cell Therapy for ischemic heart failure.
  • FDA meeting minutes support the potential use of the ongoing CardiAMP HF II trial in a U.S. approval application.
  • The company plans to discuss Helix delivery technology, Heart3D imaging and related partnering activity.

BioCardia, Inc. (NASDAQ: BCDA) will present its CardiAMP program and related technology platforms at the H.C. Wainwright conference beginning September 14 in New York.

CardiAMP and Cardiac Technology Updates

The trial is actively enrolling in the United States. Peter Altman will also discuss the Helix transendocardial delivery platform, the Heart3D Fusion Imaging platform and business development activity involving the company’s cell therapy and cardiac biotherapeutic delivery technologies.

Conference Access and Regulatory Plans

BioCardia’s prerecorded presentation was expected to become available to conference participants on September 11, while the company will not host a separate webcast. Altman and members of management will be available for one-on-one investor meetings during the conference.